Interesting that Steve states in today's webinar that CellPryme doesn't need to address all the CarT challenges as OmniCAR does address them... which is true, and was my first impression. Perhaps it doesn't
need to... but perhaps it does and that we will find out once CP-A is unveiled. Could SYC just be playing word games, so that once it's disclosed, we will be more impressed if our expectations are dumbed down a bit. Lol
Now, I think I'm onto it,
@hottod (as I suspect you are already) that CP-A is a new-improved "Activation" stage of the manufacturing cyle and that CP-M is specific to the "Expansion" stage of it (the latter is what Steve alluded to in today's webinar). So, here is how I think the two components of our CellPryme platform fits into the picture:-
CellPryme-A is all about the cell programming and activating the cells to recognise cancer but doing so via the transfection non-viral method! The following article suggests that this is where the industry is headed (including Thermo Fisher):-
https://www.frontiersin.org/articles/10.3389/fimmu.2022.867013/full
Cha-ching and ringa ding ding and all that pilava
